RxDoctor Payments Data

Margaret Pelitere, MD

Internal Medicine · New Orleans, LANPI 1154325868

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 103 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$621
  • Novo Nordisk$264
  • Lilly USA, LLC$181
  • Kowa Pharmaceuticals America, Inc.$130
  • Pfizer$127
  • Amgen$65
  • plus $388 from 13 others

What the payments were for

  • Food & beverage$1,768100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,775 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$41,220
Medicare patients
174
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$74,873
OzempicSemaglutide33$54,006
BelsomraSuvorexant53$28,142
EliquisApixaban22$20,080
JardianceEmpagliflozin22$19,530
JanuviaSitagliptin Phosphate12$18,620
LinzessLinaclotide21$14,951
Repatha SureclickEvolocumab12$8,416
SynthroidLevothyroxine Sodium64$6,177
Vilazodone Hcl15$3,289
Rosuvastatin Calcium214$2,452
Levothyroxine Sodium189$1,856
Lubiprostone11$1,586
Omega-3 Acid Ethyl Esters16$1,503
Atorvastatin Calcium171$1,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$181$74,87352 claims
Novo NordiskOzempic$264$54,00633 claims
AbbVieLinzess, Synthroid$621$21,12885 claims
PfizerEliquis$127$20,08022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →